by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS CLINICAL DATA AND COMMERCIALIZATION PLANS FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TEST AT 2020 ALZHEIMER’S DISEASE INTERNATIONAL CONFERENCE —Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer’s Disease by Identifying Patients...
by Claire | Oct 23, 2022 | Uncategorized
NEW SCIENTIFIC PUBLICATIONS SHOW DIADEM’S BLOOD-BASED ALZOSURE® BIOMARKER TEST CAN PREDICT WHICH PATIENTS WILL PROGRESS TO ALZHEIMER’S DISEASE YEARS BEFORE SYMPTOMS OCCUR —Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS NEW DATA AT AAIC® SYMPOSIUM SHOWING ITS BLOOD-BASED BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE 7 YEARS BEFORE SYMPTOMS OCCUR —Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —Longitudinal Data from 482 Patients Validates that AlzoSure® Can Predict Progression to AD Early in...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM AWARDED PATENT IN CHINA FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TECHNOLOGY THAT ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE —AlzoSure® Accurately Predicts Progression to Alzheimer’s Disease Up to Six Years Earlier than Current Diagnostic Methods—...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —AlzoSure® Predict Identifies Individuals Who Will Progress to Alzheimer’s Disease (AD) Up to Six Years...
